Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162901 · ClinicalTrials.gov registry record · NA
The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs
A NA study, sponsored by Virginia Polytechnic Institute and State University.
- Completed
- Registry status
- NA
- Development phase
- 597
- Enrollment target
NCT02162901: Completed NA study, sponsored by Virginia Polytechnic Institute and State University.
NCT02162901 is a NA study that has completed, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 597 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02162901, a NA study, has completed, sponsored by Virginia Polytechnic Institute and State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 597 participants
- Enrollment target
Study Summary
The aim of this project is to evaluate the reach, effectiveness, and costs of two patient-centered, theory-based, technology-enhanced diabetes prevention programs to initiate and sustain weight loss among pre-diabetic adults (i.e. impaired fasting glucose or impaired glucose tolerance) within a health care setting. The overall aim is consistent with the NIDDK's Behavioral/Prevention Research Program's focus on individual, family, and community-based strategies for prevention of diabetes and its complications. While evidence of lifestyle interventions that increase physical activity and improve eating habits to achieve modest weight loss in delaying and preventing the onset of type 2 diabetes continues to mount, the translation of these interventions into effective programs to health care settings with modest resources remains a challenge. The proposed research project will conduct a pragmatic clinical trial that employs a hybrid Preference/Randomized Controlled Trial (RCT) designed to compare two technology-enhanced diabetes prevention programs in achieving objectively verified weight loss relative to a standard care control at comparatively lower costs. Adult patients (18 years of age and older) at risk for developing diabetes will be randomized to either the Choice group or the Randomization group. Those patients randomized to the Choice group (n=240) will have the opportunity to choose one of two programs to participate in: 1. A 2-hour Small-Group (SG) session, with automated interactive voice response (IVR) systems targeting personal action planning to support lifestyle change and weight loss over a period of 12 months; or 2. A DVD-based intervention with the same IVR follow-up. Those patients assigned to the RCT group (n=360) will be randomized to one of three groups: 1. SG/IVR; 2. DVD/IVR; or 3. Enhanced standard-care (SC). SC includes the referral to a currently offered pre-diabetes class. Primary outcome measures include weight loss, cost, and reach of each
Primary Outcome
Weight as measured by clinical scale at baseline, and 12 months.
Interventions
- BEHAVIORAL Choice-Class with IVR Calls
- BEHAVIORAL Random-Class with IVR calls
- BEHAVIORAL Random-Class only
- BEHAVIORAL Choice-DVD with IVR calls
- BEHAVIORAL Random-DVD with IVR calls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 597 participants |
| Start Date | 2014-03-13 |
| Est. Completion | 2017-04-28 |
| Phase | NA |
What the finished NCT02162901 record still lists
NCT02162901 is an interventional study that assigns participants to a tested intervention. The registered 597 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 5 interventions - of which Choice-Class with IVR Calls is the first listed.
NCT02162901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02162901 about?
NCT02162901 is a clinical study titled "The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs". The aim of this project is to evaluate the reach, effectiveness, and costs of two patient-centered, theory-based, technology-enhanced diabetes prevention programs to initiate and sustain weight loss among pre-diabetic adults (i.e. impaired fasting glucose or impaired glucose tolerance) within a heal...
What is the current status of trial NCT02162901?
This trial is currently completed. It is a NA study. The enrollment target is 597 participants. The study started on 2014-03-13. Estimated completion is 2017-04-28.
What interventions are being tested in trial NCT02162901?
The interventions under investigation include: Choice-Class with IVR Calls (BEHAVIORAL), Random-Class with IVR calls (BEHAVIORAL), Random-Class only (BEHAVIORAL), Choice-DVD with IVR calls (BEHAVIORAL), Random-DVD with IVR calls (BEHAVIORAL).
Who is sponsoring clinical trial NCT02162901?
This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02162901's enrollment target sits among peer trials
597 174th of 2000 higher than 1,827 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI